Pfizer elevates Chris Boshoff to top R&D role
"Dr Boshoff is the ideal leader to propel Pfizer's R&D engine forward and transform it into a world-leading organisation with a more focused strategy, driving the delivery of additional impactful breakthrough medicines with blockbuster potential," said chief executive Albert Bourla.
BridgeBio Pharma Inc. gained US approval for a drug to treat a progressive and deadly form of heart disease, paving the way ...
The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...
Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...
Pfizer shares are trading lower by 10% in November. President-elect Donald Trump last week announced his intention to nominate Robert F. Kennedy Jr. to lead the HHS.
The Motley Fool on MSN3d
Is It Time to Sell Eli Lilly and Pfizer Stocks?Lilly and Pfizer stocks have sold off sharply in recent weeks. Both drugmakers have had some bad news that caused their ...
Pfizer has found a successor for retiring Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the ...
Pfizer's stock appears undervalued with a high dividend yield of 6.8%, making it a potential long-term investment despite low growth expectations. The company reported strong Q3 results with 31.2% YoY ...
Bourla said in a statement that Boshoff was “the ideal leader to propel Pfizer’s R&D engine forward and transform it into a world-leading organisation with a more focused strategy, driving the ...
For Big Pharma, recent headlines out of China suggest multinational drugmakers are facing their share of challenges in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback